Grifols Launches FESILTY for Congenital Fibrinogen Deficiency Treatment
Grifols (NASDAQ:GRFS) launched its new treatment, FESILTY, in the U.S. on June 15 to treat acute bleeding caused by congenital fibrinogen deficiency. The product is a highly purified human-derived fibrinogen concentrate that offers faster and more predictable dosing compared to traditional options like cryoprecipitate or fresh frozen plasma.
Tickers: $GRFS
Topics: biopharma FDA approval healthcare rare disease treatment